Barclays lowered the firm’s price target on UnitedHealth (UNH) to $350 from $362 and keeps an Overweight rating on the shares. Following Q1 earnings and “several negative data points” around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth former CEO made big bets on Medicare enrollees, WSJ says
- UnitedHealth price target lowered to $400 from $450 at KeyBanc
- Winners and Losers: Energy Stocks Soared and Healthcare Crashed in May
- ‘Buy Now or Regret Later,’ Says Top Investor About UnitedHealth Stock
- Why Buying the UnitedHealth (UNH) Stock Dip is a Bad Idea
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue